COMBACTE Abstracts ECCMID 2020 Available

This year the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) would have celebrated its 30th anniversary. Unfortunately the congress had to be cancelled as the COVID-19 pandemic spread. Which is why ESCMID has published all accepted abstracts in the ECCMID 2020 Abstract Book.

In the seven years of COMBACTE, lots of valuable science has been produced. As several COMBACTE studies completed recruitment, (preliminary) results have been issued.

ECCMID 2020 Abstract Book

This science would have been shared at the 30^th ECCMID in Paris this year, with a record number of 19 abstracts accepted at the congress as paper posters or oral sessions. Whilst the ECCMID unfortunately did not go ahead, the scientific abstracts that would have been presented have been added to the ECCMID 2020 Abstract Book.

The book contains results and findings from COMBACTE studies: three abstracts are featured from COMBACTE-NET, 6 from COMBACTE-MAGNET, 1 from COMBACTE-CARE and 9 from COMBACTE-CDI.

COMBACTE Abstracts

The following abstracts can be found in the Abstract Book:

COMBACTE-NET

• Abstract 565

Prophages, plasmid integration and lack of CRISPR-Cas elements underlie genome adaptation in European humanassociated Staphylococcus aureus ST398
Jelle Vlaeminck, Basil Britto Xavier, Matilda Berkell, Leen Timbermont, Christine Lammens, David E. Tabor, Jan A. J. Kluijtmans3, Willem J.B. Van Wamel, Frank E.J. Coenjaerts, Jafri S. Hasan, Bruno François, Alexey Ruzin, Herman Goossens, Surbhi Malhotra-Kumar

• Abstract 1113

Added value of throat and perineal Staphylococcus aureus screening, in addition to nasal screening, for identifying patients at risk of S. aureus surgical site infection
C. Recanatini* (Utrecht, Netherlands), D. Troeman, J. Hasan, F. Sifakis, H. Goossens, S. Malhotra-Kumar, D. Hazard, O. Ali, S. Harbarth, M. Bonten, C. van Werkhoven, J. Kluytmans

• Abstract 5344

A prediction model for identification of patients at high risk for Staphylococcus aureus intensive care unit pneumonia and implications for trial design
C. Recanatini* (Utrecht, Netherlands), F. Paling, D. Hazard, J. Hasan, O. Ali, F. Sifakis, H. Goossens, S. Malhotra-Kumar, W. Van Wamel, M. Wolkewitz, M. Bonten, J. Kluytmans

COMBACTE-MAGNET

• Abstract 2164

Systematic assessment of available data on the incidence of bloodstream infections and hospitalacquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii  in Europe: the ABOUT-MDROCRAB study
B. Anaya-Baz* (Seville, Spain), N. Maldonado, Z. Palacios Baena, V. Palomo, M. Pezzani, S. Chiesi, E. Razzaboni, M. Compri, E. Tacconelli, J. Rodríguez-Baño

• Abstract 2168

Systematic assessment of available data on the incidence of hospital-acquired pneumonia and bloodstream infections due to carbapenem-resistant Pseudomonas aeruginosa in Europe: the ABOUT-MDROCRPA project
B. Anaya-Baz* (Seville, Spain), N. Maldonado, Z. Palacios Baena, V. Palomo, M. Pezzani, S. Chiesi, E. Razzaboni, M. Compri, E. Tacconelli, J. Rodríguez-Baño

• Abstract 7146

The burden of nosocomial pneumonia caused by Pseudomonas aeruginosa and Staphylococcus aureus for ventilated patients in European intensive care units: a weighted multi-state analysis
M. Von Cube* (Freiburg, Germany), T. Bluhmki, K. Kaier, F. Sifakis, O. Ali, J. Hasan, F. Paling, J. Kluytmans, S. Malhotra-Kumar, J. Beyersmann, M. Wolkewitz

• Abstract 7556

Bridging the gap between human and animal antimicrobic resistance and consumption surveillance data, antibiotic policy and stewardship: the EPI-Net and ARCH projects
M. Pezzani* (Verona, Italy), F. Arieti, E. Carrara, R. Cauda, M. Compri, S. Goepel, F. Mazzaferri, E. Mazzolini, M. Mendelson, N. Mutters, N. Babu Rajendran, R. Schrijver, M. Sibani, A. Voss, E. Tacconelli

• Abstract 8999

Modelling pathogen transmission in intensive care units by integrating screening and antibiogram data
T. Pham* (Utrecht, Netherlands), M. Kretzschmar, X. Bertrand, M. Bootsma

• Abstract 9159

Surveillance for control of antifungal resistance in Candida bloodstream infections fails to inform antifungal stewardship in European countries
L. Galia, A. Callegari* (Spresiano, Italy), E. Carrara, N. Babu Rajendran, M. Compri, E. Tacconelli

COMBACTE-CARE

• Abstract 6296

Phenotypic and molecular characterisations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study
T. Kostyanev* (Wilrijk, Belgium), B. Xavier, M. GarcíaCastillo, C. Lammens, J. Bravo-Ferrer Acosta, J. Rodríguez-Baño, R. Canton Moreno, H. Goossens

COMBACTE-CDI

• Abstract 3490

Heterogeneity of Clostridiodes difficile infection testing and the impact on missed diagnoses: results from COMBACTE-CDI
V. Viprey, D. Ewin, W. Spittal, J. Vernon, A. Benson, G. Davis, M. Wilcox, K. Davies* (Leeds, United Kingdom)

• Abstract 3529

Healthcare resource utilisation for treatment of Clostridioides difficile infection across 12 European countries: health economic results of COMBACTE-CDI
S. Wingen-Heimann* (Cologne, Germany), L. Lurienne, K. Davies, A. Benson, G. Davis, V. Viprey, M. Wilcox, M. Bonten, O. Cornely, J. Vehreschild

• Abstract 3694

Differences in risk and outcomes for patients with Clostridium difficile toxin positive versus only cytotoxigenic culture positive faecal samples: results from COMBACTE-CDI case-control study
K. Davies* (Leeds, United Kingdom), V. Viprey, D. Ewin, A. Banz, W. Spittal, J. Vernon, A. Benson, G. Davis, P. Cleuziat, M. Wilcox

• Abstract 3744

Key differences between community and in-patient Clostridium difficile infection: results from COMBACTE-CDI case-control study
K. Davies* (Leeds, United Kingdom), V. Viprey, D. Ewin, W. Spittal, J. Vernon, A. Benson, G. Davis, M. Wilcox

• Abstract 4489

Antimicrobial susceptibility in Clostridioides difficile varies according to European region and isolate source
J. Freeman* (Leeds, United Kingdom), V. Viprey, V. Tkalec, D. Ewin, W. Spittal, E. Clark, J. Vernon, W. Fawley, A. Benson, G. Davis, M. Rupnik, M. Wilcox, K. Davies

• Abstract 4859

Current diagnosis, management and control strategies for Clostridioides difficile infection in Europe
M. Cataldo* (Rome, Italy), G. Granata, N. Petrosillo, K. Davies

Abstract 5615

European and national Clostridioides difficile infection surveillance
K. Vendrik* (Leiden, Netherlands), T. Van Der Kooi, V. Viprey, K. Davies, E. Kuijper

• Abstract 6623

Relatedness of European Clostridioides difficile strains from humans, food and animals by whole genome sequencing, ribotyping and toxinotyping; results from COMBACTE-CDI
K. Davies* (Leeds, United Kingdom), V. Viprey, V. Tkalec, N. Devos, E. Santiago-Allexant, D. Ewin, W. Spittal, J. Vernon, W. Fawley, J. Dombrecht, A. Benson, G. Davis, B. Sente, M. Rupnik, P. Cleuziat, M. Wilcox

• Abstract 6844

Current treatment pathways for Clostridioides difficile infection in Europe
N. Petrosillo* (Rome, Italy), G. Granata, M. Cataldo, K. Davies